Anyone who has been following the world of emerging pharmaceutical companies in the last few months has probably heard a good amount about the two new FDA-approved prescription weight loss drugs Qsymia and Belviq.
We don't have enough market data to properly estimate just how successful these drugs will (or will not) be when they've entered the prescription weight loss market, but if the market capitalization of Vivus (NASDAQ: VVUS) and Arena (NASDAQ: ARNA) are any indication, the market is pricing in future blockbuster status.
Often neglected in the discussion is Orexigen (NASDAQ: OREX), which has another obesity drug called Contrave being developed. Contrave is currently in a phase III trial called "The Light Study" which won't conclude until 2017 based on estimates.
Many investors are not keen on Orexigen for this reason, and waiting for the company to submit an NDA so that it can enter the obesity drug market soon. The annoying part, for OREX shareholders, is that the resubmission will probably come in 2014.
Lemon Diet
Nonetheless, Contrave has a few qualities that will distinguish it from the other two candidates later on. The drug is comprised of two active ingredients - naltrexone and bupropion.
Lemon Juice Diet
These compounds are mood-altering, like the competition, but the addition of bupropion makes it an addiction-tailored antidepressant. Bupropion is used to help smokers quit through mood elevation/stability, and research suggests that the strategy doctors employ to combat nicotine addiction can be used for food and obesity over-consumption as well.
The other active ingredient in Contrave, naltrexone, antagonizes opiate receptors. This means that the "good feeling" opioids released by the body after eating will be eliminated (or at least significantly diminished) by Contrave. Orexigen basically aims to alter patients' behavior by removing the chemistry that promotes it.
Read More: http://seekingalpha.com/article/887511-weight-loss-stocks-in-action
Fat Chance: Diet Coke Fights Obesity?
For related articles and more information, please visit OCA's Food Safety page and our Millions Against Monsanto page.
Overweight 6-Year-Old Vows To Change Lifestyle After Second Heart Attack
HOUSTON—Describing his second heart failure in the span of two years as “a real wake up call,” obese 6-year-old Nicholas Bleyer announced Tuesday that he was finally trying to turn his life around.
Obesity rates rise in county schools
By the time students in Forsyth County reach high school, more than 40 percent of them are overweight or obese, according to a BMI study released by Winston-Salem/Forsyth County Schools.
